RE:RE:RE:RE:Is it ok?Alex1726 wrote: Is $4M realistic?
- Launch of Ghryvelin™ in a number of key countries in the European Economic Area Following regional pricing approvals, Pharmanovia, our commercialization partner in the EEA, has launched Ghryvelin™ in the UK, Germany, Scandinavia and other countries in the EEA, and is expecting to launch Ghryvelin™ in additional countries in the EEA during the remainder of 2023 and into the first half of 2024
- Approval of Macrilen® in South Korea in September In South Korea, Macrilen® granules received MFDS approval in September
The largest amount of revenue will likely come from an upfront payment from a diagnostic deal in 2024. There could also be an upfront payment from a PGX deal in 2024. Gilles also said they were near launching powder beta glucan with Symrise and were also working on powder avenanthramide.
Previously Gilles said a $40 million PGX immune booster plant had a $100 million net present value. If CZO secures enough capital for an immune booster plant the market could discount a $100 million net present value with the completion of PGX scale-up to 100L. 100L itself also allows small-scale PGX commercial production.
"Gilles Gagnon, Chief Executive Officer of Ceapro, added: “The transaction provides us with the additional capital and internal capabilities to fully support near-term revenue generating cosmeceutical and nutraceutical product development programs..."